A new trading day began on Tuesday, with Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) stock price remained unchanged from the previous day of trading, before settling in for the closing price of $12.60. CNTA’s price has ranged from $8.46 to $19.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged 37.42%. With a float of $84.83 million, this company’s outstanding shares have now reached $133.55 million.
In an organization with 77 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Centessa Pharmaceuticals plc ADR (CNTA) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Centessa Pharmaceuticals plc ADR is 36.48%, while institutional ownership is 57.67%. The most recent insider transaction that took place on May 27 ’25, was worth 128,225. In this transaction Chief Business Officer of this company sold 10,000 shares at a rate of $12.82, taking the stock ownership to the 122,279 shares. Before that another transaction happened on May 27 ’25, when Company’s Officer proposed sale 10,000 for $12.82, making the entire transaction worth $128,225.
Centessa Pharmaceuticals plc ADR (CNTA) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 37.42% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.99% during the next five years compared to -210.04% drop over the previous five years of trading.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Here are Centessa Pharmaceuticals plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.37. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 111.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.48 in one year’s time.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.16 million. That was better than the volume of 0.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 68.87%. Additionally, its Average True Range was 0.75.
During the past 100 days, Centessa Pharmaceuticals plc ADR’s (CNTA) raw stochastic average was set at 31.61%, which indicates a significant decrease from 57.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.30% in the past 14 days, which was lower than the 61.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $12.58, while its 200-day Moving Average is $15.28. However, in the short run, Centessa Pharmaceuticals plc ADR’s stock first resistance to watch stands at $12.82. Second resistance stands at $13.04. The third major resistance level sits at $13.23. If the price goes on to break the first support level at $12.42, it is likely to go to the next support level at $12.23. The third support level lies at $12.01 if the price breaches the second support level.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Key Stats
With a market capitalization of 1.68 billion, the company has a total of 133,555K Shares Outstanding. Currently, annual sales are 0 K while annual income is -235,760 K. The company’s previous quarter sales were 15,000 K while its latest quarter income was -26,140 K.
